Why talis for healthcare? Remote views of clinical conditions and wave form data enable informed clinical and operational decision making, and direct communication to caregivers. Talis tools enhance patient safety and support a strong hospital and provider Return on Investment.Who is the chief operating officer of talis? Douglas Liu has served as our Chief Operating Officer since July 2021. Prior to this role, he was Talis’s Senior Vice President, Operations. From July 2005 to September 2020, Mr. Liu was Senior Vice President, Global Operations at QIAGEN N.V., a publicly held biotechnology company.What is the talis one? Talis believed there had to be a better way. By carefully analyzing the molecular diagnostic testing workflow and understanding which steps were critical for enabling the maximum amount of accuracy for infections disease identification, the team at Talis is developing a highly robust infectious disease testing solution–The Talis One.What data does talis provide at the point of interoperative care? At the point of interoperative care, Talis provides a touch-screen monitor to present the athenaOne for Hospitals' surgical schedule information, medical history and conditions, along with live physiologic data captured by our MD-iQ™ Medical Device aggregator technology.
ACG-ECMO™ is designed to unite the care team around actionable data to inform best practices of ECMO therapy. Role specific views support clinical needs. Devices. The Talis-Hub provides connection to all medical devices at an ICU bed and ECMO cart. This is the foundation of a vigilant solution that processes high-fidelity data in real time.
Our tools provide guidance at the point-of-care and beyond. Remote views of clinical conditions and wave form data enable informed clinical and operational decision making, and direct communication to caregivers. Talis tools enhance patient safety and support a strong hospital and provider Return on Investment.
Vinehealth, a 2018-founded, London-based digital health startup that’s built an app which offers personalized support for cancer patients while also making it easier to gather patient-reported outcome (PRO) data, including for drug development and clinical trials, has closed a $5.5 million seed round as it prepares to expand into the U.S.. The round, which co ...